Search results for "ONCOLOGIA"

Weekly docetaxel (wDOC) for the treatment of metastatic breast cancer (MBC): A literature based meta-analysis

2010

“The European Medicines Agency (EMEA) guideline on oncology drug development”

2007

Gemcitabine plus Oxaliplatin Folinic Acid and 5-Fluorouracil in patients with advanced gastric cancer

2004

BACKGROUND AND AIMS: oxaliplatin in combination with folinic acid (FA) and infusional 5-fluorouracil (5-FU) has shown significant anti-tumor activity in gastric cancer patients (FOLFOX). Previous studies have shown that gemcitabine (GEM), a new fluorinated anti-metabolite, enhances the individual anti-tumor activity of either 5-FU or oxaliplatin. We have therefore designed a multi-center phase II trial in order to test a novel GEM+FOLFOX-4 regimen in patients with metastatic gastric cancer. METHODS: we enrolled 36 patients, 28 males and 8 females, with an average age of 64.4 years (range 37-78), who received bi-weekly treatment with GEM (1,000 mg/m2 on day 1), levo-FA (100 mg/m2 on days 1 a…

“Final results of a phase II trial of a weekly (W) poly-chemotherapy (CT) with cisplatin (CDDP), epirubicin (EPI), fluorouracil (5FU), folinic acid (…

2009

GIST, Tumori stromali gastrointestinali (Gist: linee guida diagnostico-terapeutiche)

2009

R-Rescovitine (Seliciclib) inhibits DNA damage-induced Cyclin A1 up-regulation and hinders non-homologous end joining: a rationale for therapeutic co…

2011

[Role of loco-regional treatments for patients with breast cancer liver metastases].

2009

The role of microRNAs in driving EGFR-TKI resistance in NSCLC cell lines

2016

Background: the inhibition of EGFR kinase activity by tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, can result in improved response and prolonged progression-free survival (PFS) in NSCLC patients harboring sensitizing exon 19del and exon 21 L858R mutations. Unfortunately, almost all patients will develop resistance to EGFR-TKI, in particular T790M is the most frequent mutation. Nowadays, new methods are urgently needed for a rapid, cost-effective and non-invasive identification of biomarkers as a valuable tool for obtaining the genetic follow-up data during the course of the disease. Circulating microRNAs might represent a new precious biomarker for patients’ moni…

MRI lymphography for esophageal sentinel node mapping: evolution of a NOTES technique

2012

MRI lymphography for esophageal sentinel node mapping: evolution of a NOTES technique

EFFICACY OF ZOLEDRONIC ACID IN PATIENTS WITH RENAL CANCER METASTATIC TO BONE

2011

I in renal cancer patients probably related to survival increase. There are few data in literature about the role of BPs in the treat- ment of bone disease from colorectal cancer. We present the pre- liminary data of a large Italian multicenter retrospective analysis. Methods. 284 renal cancer patients with evidence of bone metastases have been included in the study at the moment of ab- stract submission. Patients characteristics, skeletal related events (SRE) data and median survival after bone metastases appear- ance have been collected in a master data base and statistically analyzed. The primary efficacy endpoint was time to first SRE; secondary endpoint was median survival. Results. A …